Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

ARTICLE | Emerging Company Profile

Pretzel: modulating the mitochondrial genome

Arch-incubated newco launched Monday with $72.5M and three platforms to tackle mitochondrial diseases

By Danielle Golovin, Staff Writer

September 14, 2022 11:21 PM UTC

Pretzel launched Monday with three platforms to restore mitochondrial function in a variety of indications, including both primary and secondary mitochondrial diseases, using DNA editing and small molecules.

The company debuted with a $72.5 million series A financing led by Arch Venture Partners and Mubadala Capital. HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, GV, Invus, Eir Ventures, GU Ventures and Karolinska Institute Holding also participated...